(Q43037216)

12 November 2017

title

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin (English)

1 reference

12 November 2017

1 reference

1 reference

peginterferon alfa-2b

1 reference

1 reference

1

Maria Buti

1 reference

12 November 2017

author name string

Francisco Sanchez-Avila

2

1 reference

12 November 2017

Yoav Lurie

3

1 reference

12 November 2017

Carlos Stalgis

4

1 reference

12 November 2017

Auristela Valdés

5

1 reference

12 November 2017

Maria Martell

6

1 reference

12 November 2017

Rafael Esteban

7

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

12 November 2017

1 reference

12 November 2017

volume

35

1 reference

12 November 2017

issue

4

1 reference

12 November 2017

page(s)

930-936

1 reference

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Clinical implications of hepatitis C viral kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Principles of interferon induction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.32150

21 January 2018

Identifiers

DOI

10.1053/JHEP.2002.32150

1 reference

12 November 2017

1 reference